MDC Annual Report Published, For the Year Ended 31 March 2025

National PET Imaging Platform Announces University of Cambridge as Newest Site to Receive Total-Body PET Scanner

£1m Funding for Innovative Drug Discovery Projects in Collaboration with Medicines Discovery Catapult

Launch of New Total-Body Scanner Extends UK’s World-Class Imaging Platform to Scotland

Revolutionary network of national scanners accelerates diagnosis and drug development to deliver patient benefit

Medicines Discovery Catapult and the Francis Crick Institute Partner to Support KQ Labs, a Leading Accelerator for Life Sciences Innovators

Selvita Acquires License for Medicines Discovery Catapult’s Patented Target Engagement Technology

The Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform

MDC achieves ISO 45001 health and safety standard

MDC has been awarded ISO 45001, an international standard for occupational health and safety.

Medicines Discovery Catapult Wins Bionow Business Support Award

MDC is recognised for its support of the Life Sciences sector

Commercialisation Pathway Simplified with New Regulatory Roadmap for RNA Therapeutics and Vaccines

Intracellular Drug Delivery Centre has developed the go-to guide with input from MHRA